Journal
EUROPEAN JOURNAL OF CANCER
Volume 45, Issue 7, Pages 1137-1145Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2009.03.001
Keywords
Epigenetic therapy; Acute myeloid leukaemia; Lymphoma; Histone deacetylase; DNA methyltransferase; Histone methylase and demethylase; Targeted therapy
Categories
Funding
- Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom
Ask authors/readers for more resources
Epigenetic alterations complement genetic mutations as a molecular mechanism leading to cell transformation, and maintenance of the cancer phenotype. Of note, they are reversible by pharmacological manipulation of the enzymes responsible for chromatin modification: indeed, epigenetic drugs (histone deacetylase inhibitors and DNA demethylating agents) are currently on the market inducing proliferative arrest and death of tumor cells,. These drugs, however, have been effective only in a few tumor types: the lack of consistent clinical results is mainly due to their use in a poorly targeted approach, since the epigenetic alterations present in cancer cells are mostly unknown. in a few cases (notably, leukemias expressing RAR and MLL fusion proteins), the molecular mechanisms Underlying tumor-selective and tumor-specific epigenetic alterations have started to be deciphered. These studies are revealing a dazzling complexity in the mechanisms leading to alterations of the epigenome, and the need of combination therapies targeting different chromatin modifiers to reach an effective reversion of epigenetic alterations. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available